# A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

> **NCT03251378** · PHASE1 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 129 (actual)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Colon Cancer
- Metastatic Breast Cancer
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Rectal Cancer

## Interventions

- **DRUG:** Fruquintinib (HMPL-013)

## Key facts

- **NCT ID:** NCT03251378
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-11
- **Primary completion:** 2022-12-13
- **Final completion:** 2023-03-30
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03251378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03251378, "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03251378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*